Managing Bias, Regulatory, and Inventorship Challenges Linked to AI Use in Health Care

Mintz is representing Future Electronics in an all-cash, $3.8 billion sale targeted to close in the first half of 2024. Mintz M&A Members Daniel Follansbee and Ran Zioni led a multi-office team that included Special Counsel Nicholas Perricone, plus Associates and Antitrust, Debt Financing, and Employment Members. Toronto MP Mitch Frazer and other Partners provided Canadian guidance.

The Centers for Medicare & Medicaid Services recently released the first 10 drugs included in the Inflation Reduction Act’s Medicare Drug Price Negotiation Program. Mintz Member Theresa Carnegie and Of Counsel Lauren Moldawer discuss the program, implications for drug manufacturers, and early lawsuits brought by drugmakers.

Corporate counsel can reinvigorate their companies’ DEI commitments even amid concerns generated by the Supreme Court’s affirmative action decisions and the divisive political landscape. In an article published by Corporate Counsel, ESG Practice Co-Chair and Employment Member Jen Rubin and Chief DEI Officer Narges Kakalia explored how in-house attorneys can influence corporate DEI efforts.

M&A lawyer Matthew Gardella spoke to the Wall Street Journal about factors driving the biotech M&A boom. He cited big drugmakers’ acquisitions of companies with promising assets as a strategy to offset upcoming patent expirations, low public valuations of biotech companies, a slow IPO market, and concerns about increased antitrust scrutiny.

Plaintiffs’ attorneys are increasingly bringing false advertising class action lawsuits that target companies’ inflated claims about the sustainability of their products — or “greenwashing.” Mintz litigators and energy attorneys discuss how regulators are focusing on these issues and provide an in-depth analysis of private litigation in this area.